China Universal Asset Management Co. Ltd. Has $1.32 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

China Universal Asset Management Co. Ltd. boosted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 60.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,877 shares of the specialty pharmaceutical company's stock after purchasing an additional 4,472 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Jazz Pharmaceuticals were worth $1,323,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JAZZ. State of Alaska Department of Revenue raised its position in shares of Jazz Pharmaceuticals by 387.6% during the third quarter. State of Alaska Department of Revenue now owns 33,173 shares of the specialty pharmaceutical company's stock worth $3,695,000 after acquiring an additional 26,370 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in Jazz Pharmaceuticals by 37.3% in the third quarter. DekaBank Deutsche Girozentrale now owns 115,130 shares of the specialty pharmaceutical company's stock worth $12,641,000 after purchasing an additional 31,283 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Jazz Pharmaceuticals by 15.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,476 shares of the specialty pharmaceutical company's stock valued at $275,000 after purchasing an additional 325 shares during the period. Warther Private Wealth LLC acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter worth $3,700,000. Finally, Tectonic Advisors LLC raised its position in shares of Jazz Pharmaceuticals by 6.3% during the 3rd quarter. Tectonic Advisors LLC now owns 3,891 shares of the specialty pharmaceutical company's stock valued at $433,000 after acquiring an additional 232 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company's stock, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Up 1.2 %

Shares of NASDAQ JAZZ traded up $1.37 during trading hours on Wednesday, hitting $113.28. The company had a trading volume of 145,661 shares, compared to its average volume of 670,043. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm's 50 day moving average is $110.86 and its 200-day moving average is $109.54. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.48. The stock has a market capitalization of $7.14 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 1.41 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. On average, analysts expect that Jazz Pharmaceuticals plc will post 16.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JAZZ shares. Morgan Stanley cut their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Friday, July 12th. UBS Group decreased their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a "neutral" rating for the company in a research note on Tuesday, July 2nd. Needham & Company LLC reiterated a "buy" rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $173.43.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.